The Alzheimer Society Research Portal connects researchers with Canadians looking to participate in research studies. On this website, find active studies that you can participate in to help advance research on dementia.
Informal caregivers provide much-needed support to friends, family and loved ones suffering from dementia and related conditions who continue to live at home. Smart home technologies allow providers and caregivers to monitor patients while simultaneously aiding with daily tasks such as remembering to take medications. Although smart home technology has become a common intervention with many benefits, there is very little evidence surrounding informal caregivers’ thoughts, perceptions and needs when patients are utilizing this intervention. There is a necessity to gather insights from this user group to increase uptake and proper use.
- Currently a non-medical caregiver of a dementia patient who is living at home
- Over the age of 19
- Able to read, write and speak English
Exclusion Criteria
- Caregiver of a patient who is institutionalized (e.g. living in care facility)
- Under age of 19
- Health Care Professionals (e.g. care aides, hired help)
Alert systems such as United States’ Silver Alert and Scotland’s Purple Alert support first responders in locating missing persons with dementia. In Canada, provinces are responsible for Silver Alerts. To date, Alberta and Manitoba amended Missing Persons Acts, but have no Silver Alerts. British Columbia has a citizen-led Silver Alert, yet no provincial legislation. This study examines how policies and programs for alert systems are developed and implemented in Canada, Scotland, and the United States. Findings will inform policies and implementation of alert systems to optimize the safety and well-being of people living with dementia at risk of going missing.
have experience or interest in using Silver Alert to locate missing persons with dementia and are a/an:
• Person living with dementia
• Care partner
• Alzheimer Society staff
• First responder
• Service provider
• Technology developer
• Policy maker
This Phase 2 study aims to study to evaluate the efficacy and safety of study treatment in paticipants with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Dementia
Age 50 - 80
Mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease
The purpose of this phase 2 study is to determine whether CVL-871 is safe and tolerable in patients with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.
The aim is to better understand the cognitive strengths and difficulties related to visuospatial skills among people with Mild Cognitive Impairment and/or early Alzheimer's Disease through cognitive tasks.
Follow us: